LXEO
Lexeo Therapeutics Inc.

597
Mkt Cap
$458.53M
Volume
198,971.00
52W High
$10.99
52W Low
$1.45
PE Ratio
-2.32
LXEO Fundamentals
Price
$6.43
Prev Close
$6.28
Open
$6.26
50D MA
$8.56
Beta
1.96
Avg. Volume
1.26M
EPS (Annual)
-$3.09
P/B
2.86
Rev/Employee
$0.00
$97.57
Loading...
Loading...

About

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
72

Frequently Asked Questions

What is Market Cap of Lexeo Therapeutics Inc.?
What is the 52-week high for Lexeo Therapeutics Inc.?
What is the 52-week low for Lexeo Therapeutics Inc.?
What is Lexeo Therapeutics Inc. stock price today?
What was Lexeo Therapeutics Inc. stock price yesterday?
What is the PE ratio of Lexeo Therapeutics Inc.?
What is the Price-to-Book ratio of Lexeo Therapeutics Inc.?
What is the 50-day moving average of Lexeo Therapeutics Inc.?
How many employees does Lexeo Therapeutics Inc. have?

Latest LXEO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.